Johnson & Johnson, Becoming at Least the Second Company to Pause Its Covid-19 Clinical Vaccine Trial, Due to an Unexplained Illness in a Participant.

October 13, 2020

We have temporarily paused further dosing in all our COVID-19 vaccine candidate clinical trials…

  • On October 12, Johnson & Johnson (J&J) announced it will pause all of its single-dose and two-dose regimen trials, including its Phase III ENSEMBLE trial, which began in September and aimed to enroll up to 60,000 participants.
  • It can take up to a decade for vaccines to go through the research and approval process, but J&J said it hopes to be able to supply over a 1 billion vaccine doses next year .
  • BIG PICTURE: There’s a historic vaccine development race underway, with more than 40 COVID-19 vaccine clinical trials currently underway. About a quarter of those trials are Phase III (the last stage before approval) – including at least two now-paused J& J trials.

by Jenna Lee,